Zurich, Swizerland (ots) - Recently, Solianis successfully
finalized a series of tests during which patients with diabetes have
worn its multisensor device for non-invasive glucose monitoring at
home and at work in the office. The results of these real-life tests
as well as earlier tests in a more controlled environment have
encouraged Solianis to set up the final device and prepare the market
introduction for 2010.
The results of this groundbreaking study will be presented this
year by Dr. Andreas Caduff, Solianis Chief Technology Officer, to the
world's leading diabetes experts at the most important international
conferences such as the "2nd International ATTD Conference on
Advanced Technologies & Treatments for Diabetes (ATTD)" in Athens,
the meetings of the American Diabetes Association" and the "European
Association for the Study of Diabetes".
"Solianis has reached another important milestone by successfully
closing these tests and will now present the status of its technology
to specialized audiences. This means that Solianis has earned
scientific recognition for almost four years of hard work" says Mario
Stark, CEO of Solianis. Solianis Monitoring AG is a medical devices
company developing a non-invasive Continuous Glucose Monitor (CGM)
for self-monitoring patients with diabetes. Its technology is based
on a unique and proprietary multisensor technology for monitoring
physiological parameters. Solianis' non-invasive device delivers
comparable results to the minimally invasive devices currently
approved by the FDA.
Solianis was incorporated in May 2005, and is funded by private
investors and the Pioneer Fund of the Cantonal Bank of Zurich. The
company plans to introduce its first-generation device for
insulin-dependent patients with diabetes by 2010 in Europe, after CE
approval. Later product generations will target all patients with
diabetes and impaired glucose tolerance.
ots Originaltext: Solianis Monitoring AG
Mario Stark, CEO